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Abstract
Background Stimulant medications for the treatment of
attention-deficit/hyperactivity disorder have a history of
safe and effective use; however, concerns exist that they
may adversely affect growth trajectories in children and
adolescents.
Objective The objective of this study was to evaluate the
longer-term effects of lisdexamfetamine dimesylate on
weight, height, body mass index and pubertal development
in children and adolescents with attention-deficit/hyperac-
tivity disorder.
Methods Children and adolescents aged 6–17 years with
attention-deficit/hyperactivity disorder took open-label
lisdexamfetamine dimesylate (30, 50 or 70 mg/day) in this
open-label 2-year safety and efficacy study. Safety evalu-
ations included treatment-emergent adverse events, mea-
surement of weight, height and body mass index, and self-
reported pubertal status using Tanner staging.
Results The safety analysis population comprised all
enrolled participants (N = 314) and 191 (60.8%) completed
the study. Weight decrease was reported as a treatment-
emergent adverse event in 63 participants (20.1%) and two
participants (0.6%) discontinued the study as a result of
treatment-emergent adverse events of weight decrease.
This article discusses data derived from a study described in an article
available at https://doi.org/10.1007/s40263-017-0443-y.
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s40263-018-0514-8) contains supple-
mentary material, which is available to authorized users.
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Growth retardation of moderate intensity was reported as a
treatment-emergent adverse event for two participants.
From baseline to the last on-treatment assessment, there
were increases in mean weight of 2.1 kg (standard devia-
tion 5.83) and height of 6.1 cm (standard deviation 4.90),
and a body mass index decrease of 0.5 kg/m2 (standard
deviation 1.72). Mean weight, height and body mass index
z-scores decreased over the first 36 weeks of the study and
then stabilised. Changes from baseline to the last
on-treatment assessment in mean z-scores for weight,
height and body mass index were significantly less than
zero (- 0.51, - 0.24 and - 0.59, respectively; nominal
p\ 0.0001). The proportion of participants with a z-score
of\- 1 ranged from 5.1% (baseline) to 22.1% (week 84)
for weight, 8.2% (baseline) to 12.6% (week 96) for height,
and 8.3% (baseline) to 28.8% (week 96) for body mass
index. Thirteen participants (4.1%) shifted to a weight
below the fifth percentile at the last on-treatment assess-
ment from a higher weight category at baseline. At the last
on-treatment assessment, most participants remained at
their baseline Tanner stage or had shifted higher.
Conclusions Findings from this comprehensive examina-
tion of growth outcomes associated with lisdexamfetamine
dimesylate treatment over 2 years were consistent with
previous studies of stimulant medications. Whilst mean
weight and height increased over the course of the study,
there was a small but transient reduction in mean weight,
height and body mass index z-scores. A small increase in
the proportion of participants in the lowest weight and
body mass index categories highlights the importance of
the regular monitoring of weight and height. There was no
evidence of delayed onset of puberty.
ClinicalTrials.gov identifier NCT01328756.
Key Points
This 2-year clinical study of lisdexamfetamine
dimesylate in children and adolescents with
attention-deficit/hyperactivity disorder provides the
most in-depth analysis to date of the longer-term
effect of lisdexamfetamine dimesylate on growth in
this population
Over the 2-year study, there was an increase in mean
weight and height, and a modest reduction in the
mean body mass index. Mean z-scores for weight,
height and body mass index decreased over the first
36 weeks of the study and then stabilised at this
reduced level
No clinical concerns of lisdexamfetamine dimesylate
treatment on pubertal status were observed
1 Introduction
The psychostimulants amphetamine and methylphenidate
(MPH) effectively reduce the core symptoms of attention-
deficit/hyperactivity disorder (ADHD) in children and
adolescents [1–4]. Lisdexamfetamine dimesylate (LDX) is
a long-acting amphetamine prodrug approved in USA for
the treatment of children, adolescents and adults with
ADHD [5]. Lisdexamfetamine dimesylate is approved in
some European countries for use in children aged 6 years
and older when their response to previous MPH therapy is
considered to be clinically inadequate, as well as in adults
with ADHD of at least moderate severity [6, 7]. The effi-
cacy and safety of LDX has been evaluated in a series of
short-term randomised controlled trials [8–12] and longer
term studies of up to 15 months duration [13–16]. Two of
the most frequently reported treatment-emergent adverse
events (TEAEs) in the longer term studies are decreased
appetite (reported by 21–33% of study participants) and
weight loss (16–18%). Accordingly, and in line with other
stimulant medications, LDX prescribing information rec-
ommends that weight, height and body mass index (BMI)
are closely monitored [5, 17].
SPD489-404 (ClinicalTrials.gov identifier:
NCT01328756) was a phase IV, single-arm open-label
study and was the first to evaluate the safety and efficacy of
LDX in children and adolescents with ADHD over a period
of 2 years. Improvements in symptoms were maintained
throughout the 2 years of the study, with a mean (95%
confidence intervals) change in the ADHD Rating Scale IV
(ADHD-RS-IV) total score from baseline to the last on-
treatment assessment (LOTA) of - 25.8 (- 27.0, - 24.5)
[18]. Overall, 89.8% of participants reported at least one
TEAE, with more than half (54%) reporting a decreased
appetite and 20% experiencing a decrease in weight [18].
Effects on growth and sexual development were predefined
safety outcomes in SPD489-404. We now report in detail,
changes in height, weight and BMI, at both the group and
individual level, as well as describing pubertal develop-
ment (based on Tanner staging) over the 2-year duration of
SPD489-404.
2 Methods
The study was conducted in accordance with current
applicable regulations, International Conference on Har-
monization Good Clinical Practice Guideline E6 (1996),
European Union Clinical Trials Directive 2001/20/EC
(2001) and its updates, and local ethical and legal
requirements. The study protocol was approved by an
independent ethics committee/institutional review board
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and regulatory agency in each centre (as appropriate). Each
patient’s parent/legal guardian provided written informed
consent, and assent was obtained from each participant (as
applicable) before taking part in the study. The study was
conducted between 7 July, 2011 and 30 September, 2014 at
35 sites in ten European countries (Belgium, Germany,
Hungary, Italy, the Netherlands, Poland, Romania, Spain,
Sweden, and the UK).
2.1 Study Design and Participants
Participants were enrolled either directly into this study or
had taken part in a previous LDX trial (SPD489-317
[ClinicalTrials.gov identifier: NCT01106430], SPD489-
325 [NCT00763971] or SPD489-326 [NCT00784654]).
Individuals eligible to take part were children aged
6–12 years and adolescents aged 13–17 years at the time of
consent for directly enrolled participants or at the time of
their consent into one of the previous studies. Participants
were excluded if they had been terminated from a previous
LDX study for protocol non-adherence or non-compliance
or had experienced an adverse event leading to discontin-
uation, a medication-related serious adverse event or a
clinically significant adverse event in a previous LDX
study. Patients whose current ADHD medication provided
effective control of symptoms with acceptable tolerability
were also excluded. Additional inclusion and exclusion
criteria are described in Coghill et al. [18]. All participants
were required to meet Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition—Text RevisionTM crite-
ria for a primary diagnosis of ADHD and to have an
ADHD-RS-IV total score of at least 28 at the baseline visit
(week 0). With the exception of oppositional defiant dis-
order, participants with a comorbid psychiatric diagnosis
were excluded, as were those who were significantly
underweight (defined as a BMI below the third percentile).
The plan was to enrol approximately 300 participants. The
sample size was not based on statistical considerations as
this was an open-label and uncontrolled study.
Participants received a once-daily dose of LDX (30, 50
or 70 mg) for up to 104 weeks, comprising a 4-week dose-
optimisation period followed by a 100-week dose-mainte-
nance period. During dose optimisation, weekly dose
adjustments of 20 mg/day (from a starting dose of
30 mg/day at week 0) were allowed, until an accept-
able response (defined as a 30% reduction in the ADHD-
RS-IV total score together with a Clinical Global Impres-
sion-Improvement score of 1 or 2 with tolerable side
effects) was obtained with an LDX dose between 30 and
70 mg/day. If necessary, dose adjustments were also per-
mitted during the maintenance period. Participants were
instructed to take their LDX dose each morning upon
awakening (at approximately 07:00 h).
2.2 Assessments
After the baseline assessment (week 0), visits were
scheduled every week during the dose-optimisation period
(visits 1–4; weeks 1–4). During the maintenance period,
visits were scheduled 12 weeks (± 7 days) after baseline
(visit 0, week 0) and subsequently every 12 weeks until
week 96 (visit 12). The final visit (visit 13) was scheduled
at week 104, with a safety follow-up visit at 28–30 days
(Fig. 1).
The primary objective of SPD489-404 was to evaluate
the long-term safety of LDX. Safety evaluations included
TEAEs (assessed at all visits), weight (all visits), height
(baseline and visits 5–13; weeks 0, 12, 24, 36, 48, 60, 72,
84, 96 and 104) and pubertal status (baseline and visits 5, 7,
9, 11 and 13; weeks 0, 12, 36, 60, 84 and 104). These safety
outcomes were also evaluated at an early termination visit
in participants who discontinued the study prematurely.
A TEAE of decreased weight was based on weight loss as
perceived by the participant or their carer rather than an
objective measurement of actual weight by the
investigators.
Pubertal status was self-reported using an instrument
based on the Tanner scales, which was validated in male
and female children and adolescents aged 12–16 years
[19]. Participants were shown two series of drawings that
depicted the five stages of development of external sexual
characteristics, genitalia and pubic hair in male individuals
[20] and breasts and pubic hair in female individuals [21].
Participants were required to select the drawing that most
closely represented their stage of development, with stage 1
indicating preadolescence and stage 5 indicating sexual
maturity.
2.3 Analyses
All safety outcomes were assessed in the safety analysis
population, defined as all participants who took at least one
dose of LDX during the study. For visits where height was
not measured, BMI was calculated using the last available
height measurement (last observation carried forward).
Changes from baseline in weight, height and BMI were
summarised as mean, standard deviation (SD) and range. A
potentially clinically important (PCI) change in weight was
predefined, based on clinical experience and practice [22],
as an increase or decrease of C 7% from baseline measured
at any visit. Weight, height and BMI percentiles and z-
scores were derived using the Centers for Disease Control
and Prevention (CDC) growth charts and were summarised
using predefined categories (\ 5th, C 5th to\ 95th, and
C 95th percentiles) and z-scores (\- 2, C - 2 to\- 1,
C - 1 to\ 1, C 1 to B 2, and[ 2) [23]. Weight, height
and BMI z-scores were also represented graphically by
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time using mean, median, interquartile range and 1.5 times
the interquartile range.
3 Results
3.1 Participant Disposition and Baseline
Characteristics
All 314 enrolled participants [children, n = 202 (64.3%);
adolescents, n = 112 (35.7%)] received at least one dose of
LDX and were included in the safety analysis population
[18]. Of these, 124 individuals (39.5%) had participated in
an antecedent LDX study and 190 (60.5%) were enrolled
directly. The full 2-year study was completed by 191
participants (60.8%). Reasons for early discontinuation by
more than 10% of participants were withdrawal by the
individual (n = 41, 13.1%) and adverse events (n = 39,
12.4%) [18].
Baseline demographics and disease characteristics are
summarised by Coghill et al. [18] and provided in Table 1.
At baseline, six participants (1.9%) were classified as being
underweight (BMI\ 5th percentile). The mean daily dose
of LDX across the study was 51.08 mg (SD 14.352) and
the mean duration of exposure to LDX was 555.3 days (SD
253.50, maximum possible exposure 730 days). Further
details of LDX dosing and exposure are available in the
supplementary information of Coghill et al. [18]. Overall,
303/314 participants (96.5%) were adherent to treatment
(based on tablets dispensed minus returned; adherence
designated as 80–120%). One participant had adherence
[ 120%.
3.2 Growth-Related Treatment-Emergent Adverse
Events
As reported previously based on participant and/or carer
report, overall, TEAEs were reported for 282 participants
(89.8%) [18]. Weight decrease was reported as a TEAE for
63 participants [20.1%; children, n = 33 (16.3%);
adolescents, n = 30 (26.8%)], and two participants (0.6%;
both children) discontinued the study as a result of weight
decrease TEAEs. Growth retardation of moderate intensity
was reported as a TEAE for two participants (0.6%; one
child and one adolescent).
3.3 Changes in Weight, Height and Body Mass
Index
From baseline to LOTA, there was a mean weight increase
of 2.1 kg (SD 5.83; range, - 20 to ? 34 kg), a mean
height increase of 6.1 cm (SD 4.90; range, - 1 to 20 cm)
and a mean BMI decrease of 0.5 kg/m2 (SD 1.72; range,
- 7 to ? 10 kg/m2). The mean weight decreased by up to
1.9 kg from baseline during the first 24 weeks and then
increased throughout the remainder of the study (Fig. 2a).
Mean height increased throughout the study (Fig. 2b).
There was a small decrease from baseline in BMI, which
reached a nadir (- 1.2 kg/m2) at weeks 24 and 36 before
beginning to recover towards the baseline value (Fig. 2c).
Changes in weight, height and BMI z-scores and per-
centiles are presented below.
A PCI decrease in weight (C 7% loss from baseline)
was reported for 112/313 participants (35.8%) at any study
visit. The largest number of PCI decreases in weight from
baseline was reported at week 24 [72/272 (26.5%)]. At
LOTA, a PCI decrease in weight from baseline was
reported for 33/313 participants (10.5%). A PCI increase in
weight from baseline at any study visit was reported in
129/313 participants (41.2%). The largest proportion of
PCI increases in weight from baseline was observed at
week 104 [99/189 (52.4%)]. At LOTA, a PCI increase in
weight from baseline was reported for 119/313 participants
(38.0%).
3.4 Changes in Weight, Height and Body Mass
Index Z-Scores
During the first 36 weeks of the study, mean z-scores for
weight, height and BMI declined by 0.52, 0.15 and 0.63,
30 mg 
70 mg 
50 mg LDX 
Dose-optimization
period
Dose-maintenance
period 
Baseline
Screening
Safety
follow-up
Study week 
Study visit 
–6 to –1 1 2 3 3624124 48
–1 10 2 3 7654 14
60 72 84 96 104 108
8 1211109 13/ET
Fig. 1 SPD489-404 study design. ET early termination, LDX lisdexamfetamine dimesylate
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respectively, and then remained generally stable to LOTA
(Figs. 2d–f). Changes from baseline to LOTA in mean
z-scores for weight, height and BMI were significantly less
than zero (- 0.51, - 0.24 and - 0.59, respectively;
nominal p\ 0.0001; Table S1 of the Electronic Supple-
mentary Material [ESM]). Figure 3 shows the proportions
of participants in each z-score category (\ – 2, C – 2 to
\ – 1, C – 1 to \ 1, C 1 to B 2, and [ 2) for weight,
height and BMI at each study visit. Throughout the study
and at LOTA, the majority of participants were within 1
SD of the CDC mean (i.e. were in the C – 1 to\ 1 cate-
gory) for weight (range, 62.7% at baseline and visit
11–72.2% at visit 7), height (range, 53.8% at baseline
to 63.6% at visit 12) and BMI (range, 58.7% at visit
1–64.3% at visit 5). Proportions of participants with a
z-score of\ – 1 ranged from 5.1% at baseline to 22.1% at
visit 11 for weight, 8.2% at baseline to 12.6% at visit 12 for
height and 8.3% at baseline to 28.8% at visit 12 for BMI
(Fig. 3). Proportions of participants with weight, height or
BMI z-scores 2 SD or more below the CDC population
norm ranged from 0.6% at baseline to 3.9% at visit 11 for
weight, 0.5% at visit 13 to 1.5% at visit 11 for height and
1.3% at baseline to 6.4% at visit 11 for BMI.
Similarly, at LOTA, most participants remained within
their baseline percentile category (\ 5th, C 5th to\ 95th,
C 95th) for weight [276/314 (87.9%)], height [263/314
(83.8%)] and BMI [275/314 (87.6%)] (Table 2). At LOTA,
the increase in the number (%) of participants in the\ 5th
percentile category compared with baseline was 13 (4.1%)
for weight, 3 (1.0%) for height and 26 (8.3%) for BMI. Of
the 13 participants in the \ 5th percentile category at
LOTA for weight, four had weight decrease reported as a
TEAE, eight completed the study, two withdrew and three
discontinued the study owing to an adverse event (weight
gain poor, n = 1; orthostatic hypotension, n = 1; and irri-
tability, n = 1).
3.5 Tanner Staging
At baseline, approximately 30% of all participants were at
Tanner stage 1, based on self-reported pubic hair and
genitalia development (male individuals) or pubic hair and
breast development (female individuals) (Table 3). Almost
all participants who were at Tanner stage 1 at baseline were
aged 6–12 years (female individuals, 100%; male indi-
viduals,[ 97%), with approximately half of all children
aged 6–12 years being at Tanner stage 1 at baseline. In
contrast, most participants who were at Tanner stage 4 or 5
at baseline were adolescents aged 13–17 years. The
majority of adolescents (male individuals,[ 66%; female
Table 1 Baseline
demographics and disease
characteristics [18]
Characteristic Safety analysis population (N = 314)
Age, year, n (%) 11.4 ± 2.88 (6–19)a
6–12 202 (64.3)
13–17a 112 (35.7)
Sex, male, n (%) 250 (79.6)
Weight, kg 46.13 ± 16.434 (23.0–99.5)
Height, cm 152.29 ± 16.633 (113.5–189.4)
BMIb, kg/m2 19.22 ± 3.389 (13.0–29.8)
BMI categoriesb,c, n (%)
Underweight (\ 5th percentile) 6 (1.9)
Normal (C 5th to\ 85th percentile) 208 (66.2)
Overweight (C 85th to\ 95th percentile) 83 (26.4)
Obese (C 95th percentile) 17 (5.4)
ADHD-RS-IV total score 41.1 ± 7.03 (17–54)d
Any prior ADHD medication, n (%) 271 (86.3)
Values are mean ± standard deviation (range) unless otherwise stated
ADHD attention-deficit hyperactivity disorder, ADHD-RS-IV Attention-Deficit/Hyperactivity Disorder
Rating Scale IV, BMI body mass index
aFour participants were aged[ 17 years at baseline and were included in the 13–17 years age category.
These participants were enrolled because, for study eligibility purposes only, age was based on the age at
the time of consent for this study, or for the previous lisdexamfetamine dimesylate study if applicable
bCalculated at baseline
cCenters for Disease Control BMI categories for children and adolescents
dOne participant had a score of 17, which was lower than the protocol-specified value of C 28; this was
recorded as a protocol deviation/violation
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individuals, [ 78%) were at Tanner stages 4 or 5 at
baseline.
Mean age at each Tanner stage at LOTA for male and
female individuals is summarised in Table S2 of the ESM.
Sexual maturation, as indicated by shifts to a higher Tanner
stage from baseline to LOTA, was reported by nearly half
of the participants of all ages (pubic hair development:
49.0% male individuals, 44.4% female individuals; genital/
breast development: 46.7% male individuals, 39.7% female
individuals) (Table 3). In participants aged 6–12 years,
proportions of participants shifting to a higher stage at
LOTA than baseline were 50.3% for male individuals and
57.1% for female individuals based on pubic hair devel-
opment, and 48.4% for male individuals and 54.3% for
female individuals based on genital/breast development. In
participants aged 13–17 years, the proportions of partici-
pants reporting shifts from a lower to a higher Tanner stage
were 46.4% for male individuals and 28.6% for female
individuals based on pubic hair development, and 43.4%
for male individuals and 21.4% for female individuals
based on genital/breast development.
Approximately half of all participants remained at the
same Tanner stage from baseline to LOTA (pubic hair
development: 46.5% male individuals, 47.6% female
individuals; genital/breast development: 48.0% male indi-
viduals, 58.7% female individuals). In participants aged
6–12 years, the proportions of participants remaining at the
same Tanner stage from baseline to LOTA were 46.6% for
male individuals and 37.1% for female individuals based
on pubic hair development, and 47.2% for male individuals
and 45.7% for female individuals based on genital/breast
development. In the 13–17 year age group, 46.4% of male
individuals and 60.7% of female individuals remained at
the same Tanner stage at LOTA as at baseline based on
pubic hair development and 49.4% of male individuals and
75.0% of female individuals based on genital/breast
development.
Shifts to a lower Tanner stage were reported by less than
8% of all participants (pubic hair development: 4.5% male
individuals, 7.9% female individuals; genital/breast
development: 5.3% male individuals, 1.6% female indi-
viduals). In participants aged 6–12 years, 3.1% of male
individuals and 5.7% of female individuals shifted from a
higher to a lower Tanner stage based on pubic hair
development, and 4.3% of male individuals and 0.0% of
female individuals shifted to a lower Tanner stage based on
genital/breast development. In the 13–17 year age group,
7.1% of male individuals and 10.7% of female individuals
shifted from a higher to a lower Tanner stage based on
pubic hair development, and 7.2% of male individuals and
3.6% of female individuals based on genital/breast
development.
4 Discussion
Regulators have recommended that, to address a relative
lack of data about certain potential aspects of the longer
term clinical safety of ADHD medications, clinical trials
should assess, among other factors, growth, alterations in
weight and sexual maturation [24]. Here, we report the
weight, height and BMI data from the first 2-year clinical
study of LDX. These data provide the most in-depth
analysis to date of the longer term effects of LDX on
weight, height and BMI in children and adolescents with
ADHD. In addition, this was the first study to examine the
impact of LDX treatment on pubertal development. Over
the 2-year study, there was an increase in mean weight and
height, and a modest reduction in mean BMI. Z-scores
decreased over the first half of the study and then stabilised
for weight, height and BMI. Similar proportions of par-
ticipants were within 1 SD of the CDC population norms
for weight, height and BMI at both baseline and LOTA.
However, the proportion of participants who were more
than 1 SD below the CDC population norms increased
from baseline to LOTA for weight, height and BMI. A
small proportion of participants (B 7% at any study visit)
were recorded with values more than 2 SD below the CDC
population norm for weight, height and BMI. In addition,
more than 80% of participants remained within their
baseline percentile category for weight, height and BMI at
LOTA, and some experienced PCI changes in weight of
C 7% from baseline. While increases in weight would be
expected over the course of the 2-year study, a decrease in
weight of C 7% from baseline occurred in approximately
one-tenth of participants at LOTA. Overall, at LOTA, most
participants had progressed higher or remained at their
baseline Tanner stage, suggesting that longer term LDX
treatment was not associated with any clinically concerning
trends in pubertal development.
The findings on growth are consistent with those of a
previous study that demonstrated that children with ADHD
receiving LDX for up to 15 months had statistically
bFig. 2 Changes from baseline (BL) in a weight, b height and c body
mass index (BMI), and z-score box plots for d weight, e height and
f BMI at each study visit and last on-treatment assessment (LOTA)
[safety analysis population; N = 314]. In parts a–c, the filled diamond
represents the mean, the box represents the standard deviation and the
whiskers indicate the range (minimum, maximum). In parts d–f, the
filled diamond represents the mean, the box represents the interquar-
tile range, the whiskers indicate 1.5 times the interquartile range and
the filled circle represents outliers (values outside 1.5 times the
interquartile range). The z-scores were derived using Centers for
Disease Control and Prevention growth charts [23]. For calculation of
the BMI, for visits where height was not measured or if height was
missing, the last observation carried forward value for height was
used
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significant mean reductions from baseline in weight, height
and BMI z-scores compared with CDC population norms,
with the greatest reductions in weight gain seen within the
first 6 months [14]. In the previous study, the greatest
impacts on growth were observed in the heaviest and tallest
children, those who had not previously received stimulant
treatment and those with a greater cumulative exposure to
LDX [14]. The findings of the current study are also in line
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with longer term investigations of other psychostimulants
on growth outcomes in children and adolescents with
ADHD, which have consistently reported deficits in
weight, height and BMI compared with age-adjusted pop-
ulation norms during the initial stages of stimulant treat-
ment. The treatment of children with ADHD with
transdermal MPH for up to 36 months was associated with
small but statistically significant delays in weight, height
and BMI attainment that occurred mainly in the first year
and attenuated over time [25]. In this study, growth deficits
were more frequent among the heaviest and tallest chil-
dren, and in those who had not previously received stim-
ulant therapy. Slight decreases in mean weight were also
observed in the first 4 months of a 21-month study of
osmotic-release oral system MPH in children with ADHD
[26, 27]. These weight changes then stabilised and were
considered to be clinically insignificant. The decrease in
growth z-scores was smaller in individuals who had
received previous stimulant therapy than in those not pre-
viously treated [26]. Treatment with extended-release
mixed amphetamine salts was associated with reductions in
expected height and weight gains in a 30-month study in
children with ADHD [27]. Again, nearly all of the growth
deficits occurred in the first year of treatment. [27].
While the evidence is compelling that the early stages of
stimulant treatment are associated with a modest reduction
in weight gain, less is known about the long-term effects of
stimulant treatment on growth [28]. In a naturalistic
10-year prospective study in children with ADHD, stimu-
lant therapy (using an amphetamine product, MPH product
or pemoline) had no effect on growth [29]. More recently, a
16-year follow-up study of 515 individuals with ADHD
found extended use of stimulant medication to be associ-
ated with a suppression of adult height (in most cases, the
stimulant medication was immediate-release MPH) [30]. A
meta-analysis of longitudinal studies in children with
ADHD receiving stimulants for at least 1 year found sig-
nificant delays in weight and height attainment during the
early stages of treatment, but these effects attenuated over
time [28]. This meta-analysis also found that in most head-
Table 2 Shifts in weight, height and body mass index (BMI) category from baseline to last on-treatment assessment (LOTA) [safety analysis
population, N = 314]
LOTA
\ 5th
percentile
n (%)
C 5th to\ 95th percentile
n (%)
C 95th
percentile
n (%)
Missing
n (%)
Total
(baseline)
n (%)
Weight category
Baseline \ 5th percentile 3 (1.0) 1 (0.3) 0 0 4 (1.3)
C 5th percentile to\ 95th
percentile
13 (4.1) 255 (81.2) 4 (1.3) 1 (0.3) 273 (86.9)
C 95th percentile 0 19 (6.1) 18 (5.7) 0 37 (11.8)
Missing 0 0 0 0 0
Total (LOTA) 16 (5.1) 275 (87.6) 22 (7.0) 1 (0.3) 314 (100)
Height category
Baseline \ 5th percentile 4 (1.3) 2 (0.6) 0 0 6 (1.9)
C 5th percentile to\ 95th
percentile
3 (1.0) 230 (73.2) 8 (2.5) 11 (3.5) 252 (80.3)
C 95th percentile 0 25 (8.0) 29 (9.2) 2 (0.6) 56 (17.8)
Missing 0 0 0 0 0
Total (LOTA) 7 (2.2) 257 (81.8) 37 (11.8) 13 (4.1) 314 (100)
BMI category
Baseline \ 5th percentile 5 (1.6) 1 (0.3) 0 0 6 (1.9)
C 5th percentile to\ 95th
percentile
26 (8.3) 267 (85.0) 4 (1.3) 1 (0.3) 298 (94.9)
C 95th percentile 0 7 (2.2) 3 (1.0) 0 10 (3.2)
Missing 0 0 0 0 0
Total (LOTA) 31 (9.9) 275 (87.6) 7 (2.2) 1 (0.3) 314 (100)
Italics indicate participants who remained in the same percentile category; bold indicates participants who shifted to a lower percentile category;
bold italics indicate participants who shifted to a higher percentile category. For calculating BMI, if a height measurement was missing, the last
observation carried forward value was used
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to-head studies of MPH vs. amphetamine, no differences
were observed between these two stimulants in their effects
on growth suppression, perhaps because both stimulants
increase brain extracellular dopamine concentration, and
increased dopamine levels may be associated with inhibi-
tion of the growth hormone through dopamine D2 receptors
in the pituitary [31].
Attention-deficit hyperactivity disorder itself may be
associated with dysregulated growth and may, therefore,
confound the interpretation of growth data from uncon-
trolled studies of ADHD medications [32, 33]. In a cross-
sectional analysis of 62,887 children and adolescents, those
with ADHD who were not currently receiving medication
had 1.5 times the odds of being overweight compared with
those without ADHD, with the authors suggesting that
impulsivity and poor regulation of behaviour may increase
the risk of developing poor eating patterns [34]. In the
same study, children and adolescents who were currently
receiving medication for ADHD were 1.6 times more likely
to be underweight than those without ADHD. However, a
10-year longitudinal case–control study in 522 children
found no association between ADHD and dysregulated
Table 3 Shifts in Tanner staging from baseline to endpoint (safety analysis population, N = 314)
Male individuals (overall; n = 250) LOTA
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Total
Hair development
Baseline Stage 1, n (%) 35 (14.3) 31 (12.7) 15 (6.1) 2 (0.8) 0 83 (33.9)
Stage 2, n (%) 2 (0.8) 19 (7.8) 14 (5.7) 8 (3.3) 2 (0.8) 45 (18.4)
Stage 3, n (%) 1 (0.4) 4 (1.6) 14 (5.7) 22 (9.0) 3 (1.2) 44 (18.0)
Stage 4, n (%) 0 0 1 (0.4) 35 (14.3) 23 (9.4) 59 (24.1)
Stage 5, n (%) 0 0 0 3 (1.2) 11 (4.5) 14 (5.7)
Total (LOTA) 38 (15.5) 54 (22.0) 44 (18.0) 70 (28.6) 39 (15.9) 245 (100)
Genitalia development
Baseline Stage 1, n (%) 25 (10.2) 30 (12.3) 13 (5.3) 2 (0.8) 0 70 (28.7)
Stage 2, n (%) 4 (1.6) 29 (11.9) 11 (4.5) 10 (4.1) 1 (0.4) 55 (22.5)
Stage 3, n (%) 2 (0.8) 1 (0.4) 19 (7.8) 23 (9.4) 2 (0.8) 47 (19.3)
Stage 4, n (%) 0 1 (0.4) 1 (0.4) 29 (11.9) 22 (9.0) 53 (21.7)
Stage 5, n (%) 0 0 0 4 (1.6) 15 (6.1) 19 (7.8)
Total (LOTA) 31 (12.7) 61 (25.0) 44 (18.0) 68 (27.9) 40 (16.4) 244 (100)
Female individuals (overall; n = 64) LOTA
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Total
Hair development
Baseline Stage 1, n (%) 9 (14.3) 4 (6.3) 4 (6.3) 2 (3.2) 0 19 (30.2)
Stage 2, n (%) 0 2 (3.2) 3 (4.8) 4 (6.3) 1 (1.6) 10 (15.9)
Stage 3, n (%) 0 0 3 (4.8) 6 (9.5) 0 9 (14.3)
Stage 4, n (%) 0 0 2 (3.2) 9 (14.3) 4 (6.3) 15 (23.8)
Stage 5, n (%) 0 0 0 3 (4.8) 7 (11.1) 10 (15.9)
Total (LOTA) 9 (14.3) 6 (9.5) 12 (19.0) 24 (38.1) 12 (19.0) 63 (100)
Breast development
Baseline Stage 1, n (%) 10 (15.9) 4 (6.3) 3 (4.8) 1 (1.6) 0 18 (28.6)
Stage 2, n (%) 0 2 (3.2) 5 (7.9) 4 (6.3) 0 11 (17.5)
Stage 3, n (%) 0 0 6 (9.5) 3 (4.8) 0 9 (14.3)
Stage 4, n (%) 0 0 0 12 (19.0) 5 (7.9) 17 (27.0)
Stage 5, n (%) 0 0 0 1 (1.6) 7 (11.1) 8 (12.7)
Total (LOTA) 10 (15.9) 6 (9.5) 14 (22.2) 21 (33.3) 12 (19.0) 63 (100)
Italics indicate participants with the same Tanner score at baseline and LOTA; bold indicate participants with an increase from baseline in Tanner
score at LOTA; bold italics indicate participants with a decrease from baseline in Tanner score at LOTA
LOTA last on-treatment assessment
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growth [29], and in the Multimodal Treatment Study of
Children with ADHD, newly medicated individuals had a
similar mean weight z-score at baseline to non-medicated
children, although the mean height z-score was lower for
the newly medicated group at baseline and at each subse-
quent assessment [35]. Notably, in the present study, as
well as in certain other studies in children and adolescents
with ADHD [14, 25], mean z-scores at baseline were above
the CDC population mean. It may be that individuals with
ADHD are heavier and taller than the age-adjusted popu-
lation norms, or it may be that the CDC norms developed
in the year 2000 are no longer fully representative of the
normal population.
This was the first study to explore whether LDX therapy
impairs pubertal development in children and adolescents
with ADHD; however, interpretation of our findings is
inhibited because of a lack of good quality normative data
about pubertal development and associated population
norms for Tanner staging for comparison. In a study of
American adolescents without ADHD, Tanner stage 2 was
achieved in the age range of 11.9–12.3 years for male
individuals and 11.2–11.9 years for female individuals,
stage 3 at 13.2–13.9 years for boys and 12.4–12.7 years for
female individuals, stage 4 at 14.3–14.7 years for boys and
13.1–13.4 years for female individuals and stage 5 at
15.1–15.3 years for male individuals and 14.5–14.6 years
for female individuals [36]. These data are broadly con-
sistent with the findings from SPD489-404, in which all
participants who were at Tanner stage 1 at LOTA were
aged 12 years or younger and most participants aged
13 years or older were at Tanner stages 2–5, suggesting
that pubertal development is broadly similar in children
and adolescents with and without ADHD.
In SPD489-404, the observation that the majority of
participants remained at their baseline Tanner stage or
progressed higher does not suggest that LDX treatment has
a clinically concerning impact on pubertal development.
The possibility, however, that staying at the same Tanner
stage may represent a delay in pubertal development in
some individuals cannot be discounted. These findings are
broadly consistent with data from the 3-year follow-up of
the Multimodal Treatment Study of Children with ADHD,
which found no statistically significant differences in sex-
ual development between children with or without ADHD,
and that stimulant medication had no apparent effect on
sexual development [37]. However, a study of boys with
ADHD aged 12–15 years who had received stimulant
treatment for more than 3 years demonstrated that those in
the 14–15 years age group were significantly behind
untreated controls in height and pubertal development [38].
Pubertal regression has been reported in certain hor-
monal conditions such as hypopituitarism but is generally
uncommon [39]. In a study designed to validate the
Pubertal Development Scale in 253 healthy adolescent
male and female individuals, the authors concluded that
inaccuracies in self-assessment were responsible for the
9.8% of male individuals and 6.4% of female individuals
who reported a decrease in sexual development [40]. The
tendency for individuals to overestimate their development
during the early stages of puberty and underestimate it
during the later stages [41] supports the notion that the
small number of shifts from a higher to a lower Tanner
stage in SPD489-404 may be the result of inaccurate self-
reporting. It should be noted that Tanner staging has only
been validated in 12- to 16-year-old individuals, suggesting
that assessment of sexual development in individuals
below this age range may not be accurately assessed by the
instrument. However, the occasional regression of pubertal
development in SPD489-404 cannot be entirely excluded.
The strengths of this study include the large number of
participants enrolled at multiple sites, its 2-year duration,
the range of approaches used to measure growth and the
assessment of pubertal development. Important limitations
are the open-label design, lack of a control arm and
potential inconsistencies in the self-assessment of pubertal
development. In addition, recruitment from antecedent
studies is likely to have enriched the study population with
individuals with good tolerability to LDX and for whom
the changes in growth described here may have already
taken place. Furthermore, the study design does not permit
further exploratory analyses between growth and other
parameters such as age and puberty. A substantial pro-
portion of the participants had received prior stimulant
medications, which may have masked the full impact of the
initiation of LDX treatment on growth in stimulant-naı¨ve
participants; however, the number of participants who were
treatment naı¨ve was too small to permit a robust subgroup
analysis. Analysis of male and female subgroups was also
not possible because the study population included rela-
tively few female individuals.
5 Conclusions
Over the course of this 2-year study of LDX in children and
adolescents with ADHD, mean weight and height
increased. Although deficits compared with CDC popula-
tion norms were observed in weight, height and BMI, these
occurred early in the study and then stabilised. Most par-
ticipants remained at their baseline Tanner stage or shifted
to a higher stage. There was no evidence of a delayed onset
of puberty, although a possible delay in the onset of pub-
erty in some individuals cannot be discounted. These
findings enhance our understanding of the effects of LDX
on growth and pubertal development, and support recom-
mendations for the regular monitoring of growth and
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development of children and adolescents receiving stimu-
lants in clinical practice [17, 42].
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